Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Kung Fu Thai & Chinese Restaurant Expands Egg Foo Young Menu With Shrimp and Beef SelectionsLAS VEGAS, NV - August 27, 2026 -
- Gilead Sciences, Inc.U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex RegimensCompanies: Gilead SciencesFOSTER CITY, Calif., August 27, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed.
- Healthy Choice Wellness Corp. Announces 1-for-35 Reverse Stock SplitHealthy Choice Wellness Corp. (NYSE American: HCWC) (the “Company”), a holding company focused on the natural and organic grocery sector, today announced that its Board of Directors (the “Board”) has approved a one-for-thirty-five (1:35) reverse stock split (the “Reverse Stock Split”) of the Company’s Class A common stock, par value $0.001 per share (the “Common Stock”), that is expected to become effective on August 28, 2026 at 11:59 p.m., Eastern Time (the “Effective Time”). The Common Stock will continue to trade on the NYSE American under the symbol “HCWC” and is expected to begin trading on a split-adjusted basis upon market open on Monday, August 31, 2026. The new CUSIP number for the Common Stock following the Reverse Stock Split will be 42227T303.
- Groupe Prime Drink fournit un rapport bihebdomadaire sur le statut du MCTOMONTRÉAL, 27 août 2026 -- Groupe Prime Drink Corp. (CSE : PRME) (« Prime » ou la « Société ») annonce que, conformément à ses communiqués de presse du 30 juillet et du 14 août 2026, la Société a volontairement déposé une demande auprès de son autorité principale, la British Columbia Securities Commission (« BCSC »), qui a accordé un ordre d’interdiction d’opérations aux dirigeants (« MCTO ») daté du 30 juillet 2026, en vertu de la Politique nationale 12-203 — Ordres d’interdiction d’opérations aux dirigeants (« NP 12-203 »), et a accordé à la Société un délai supplémentaire pour déposer ses états financiers annuels pour la période terminée le 31 mars 2026, y compris le rapport de gestion et les attestations connexes du chef de la direction et du chef de la direction financière, au plus tard le 29 juillet 2026 (collectivement, les « Déclarations financières annuelles »). Ce délai a été prolongé jusqu’au 28 septembre 2026 inclusivement.
- Prime Drink Group Provides Bi-Weekly MCTO Status ReportPrime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that further to its news releases dated July 30 and August 14, 2026, the Company voluntarily applied for and the Company’s principal regulator, the British Columbia Securities Commission (the “BCSC”) granted a management cease trade order (the “MCTO”) dated July 30, 2026, under National Policy 12-203 Management Cease Trade Orders (“NP 12-203”) and provided the Company with an extension to file its annual financial statements for the year ended March 31, 2026, including the related management’s discussion and analysis, and Chief Executive Officer and Chief Financial certifications on or before July 29, 2026 (collectively the “Annual Financial Filings”). The deadline has been extended to on or before September 28, 2026.
- Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 VaccineCompanies: PfizerPfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies’ 2026-2027 COVID-19 vaccine formula targeting the XFG variant (COMIRNATY® XFG; COVID-19 Vaccine, mRNA) for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.1
- Pfizer Inc.Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 VaccineCompanies: PfizerNEW YORK & MAINZ, Germany, August 27, 2026--Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies’ 2026-2027 COVID-19 vaccine formula targeting the XFG variant (COMIRNATY® XFG; COVID-19 Vaccine, mRNA) for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying cond
- FDA Issues Emergency Use Authorization for Generic Drug to Prevent New World Screwworm in CattleThe U.S. Food and Drug Administration today issued an Emergency Use Authorization (EUA) for Bimectin (ivermectin) injection for the prevention of New World screwworm (NWS) infestations (myiasis) in cattle when administered within 24 hours of birth, at the time of castration, or at the appearance of a wound – advancing the Trump Administration's goal of safeguarding American agriculture from NWS. Bimectin injection is not authorized for use in lactating dairy cows or in calves that will be processed for veal.
- The World's Leading Minds in Biotechnology Will Meet in Riyadh This SeptemberRIYADH, KSA, Aug 28, 2026 - The Riyadh Global Medical Biotechnology Summit has published the scientific program for its fourth edition, and the names on it belong to the people currently deciding what medicine will be able to do in the next twenty years. Sixty confirmed speakers and moderators from eleven countries are named across three days, from 14 to 16 September 2026, at the Sofitel Riyadh Hotel and Convention Centre. Among them are Prof. Jin-Soo Kim of KAIST, whose work on mitochondrial DNA editing reaches beyond CRISPR; Dr. Matthew H. Porteus of Stanford University, engineering genetic circuits into cell-based medicines; Dr. Alex Shalek of MIT; Prof. Vijay Kuchroo of Harvard Medical School; Prof. Keith T. Flaherty of the Massachusetts General Hospital Cancer Center and President of the American Association for Cancer Research; Prof. George F. Gao of the Chinese Academy of Sciences; President Mitsuo Ochi of Hiroshima University; and Dr. Zdenko Herceg of the International Agency for Research on Cancer. They are joined by the people who move science into the world. Dr. Steve Yang, Co-CEO of WuXi AppTec, and Mr. Alec Reynolds of Flagship Pioneering open the program on global partnership. Mr. Kasim Kutay, Chief Executive Officer of Novo Holdings, speaks on where capital should go next. Dr. Hyun-Young Park, Deputy Minister of the Korea National Institute of Health, delivers the closing keynote. Alongside them stand the Saudi institutions building a biotechnology sector in real time: KAIMRC, Lifera, HUMAIN, SPIMACO, KAUST, the Saudi Food and Drug Authority, and Astronaut Rayyanah Barnawi on what the human immune system does in space. The program runs across six tracks: artificial intelligence in biotechnology, multi-omics, biotech investment, immunology, bioengineering and synthetic biology, and biotech workforce development. Its defining feature is that discovery and delivery share the same stage. Genome editing and population genomics sit beside regulation, domestic manufacturing, and procurement, and in several sessions the scientists and the regulators are on the same panel. That is the premise of the Kingdom's National Biotechnology Strategy, which targets $34.6 billion in non-oil GDP from biotechnology by 2040: a discovery is worth only as much as the system available to carry it to a patient. "Biotechnology is where the health of every nation will be decided over the next twenty years. Saudi Arabia has chosen not to watch that happen from a distance. We are building the laboratories, the manufacturing, the regulatory ecosystems, and above all, the bio-workforce talent. And we are building it in partnership with the world, under one roof. That is what this Summit is for. Its themes highlight where medicine and biotechnology converge to shape the future of biosciences. Discoveries and breakthroughs are transforming how we care for patients. The diversity of emerging technologies and therapies is creating significant opportunities to explore, advance, invest, and translate scientific progress into better health outcomes. Please join us in Riyadh this September." H.E. Prof. Bandar bin Abdulmohsen Al-Knawy, Chief Executive Officer of Health Affairs, Ministry of National Guard, and President, King Saud bin Abdulaziz University for Health Sciences The Summit is organized and supervised by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by King Abdullah International Medical Research Center (KAIMRC) and King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), with the Ministry of Investment and Invest Saudi serving as strategic partners. The fourth edition is expected to welcome more than 15,000 visitors, over 200 biotechnology and healthcare brands, and delegations from more than 70 countries, under the theme Building the Foundations of Biotechnology Excellence. The full scientific program is attached and available at rgmbs.org, where registration is open for delegates, exhibitors, and industry partners. Follow the Summit at #RGMBS2026. For further information regarding summit programing visit: https://rgmbs.org/program#conference-agenda About the Riyadh Global Medical Biotechnology Summit The Riyadh Global Medical Biotechnology Summit is the Kingdom of Saudi Arabia's flagship platform for medical biotechnology, convening the global scientific, investment, and policy communities in Riyadh. Organized and supervised by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by KAIMRC and KSAU-HS, the Summit advances the goals of the National Biotechnology Strategy and supports the Kingdom's emergence as a global destination for health innovation. The fourth edition takes place from 14 to 16 September 2026 in Riyadh. For Media Inquiry Email: [email protected] Telephone: +966 559 810 777
- The World's Leading Minds in Biotechnology Will Meet in Riyadh This SeptemberRIYADH, KSA, Aug 28, 2026 - The Riyadh Global Medical Biotechnology Summit has published the scientific program for its fourth edition, and the names on it belong to the people currently deciding what medicine will be able to do in the next twenty years. Sixty confirmed speakers and moderators from eleven countries are named across three days, from 14 to 16 September 2026, at the Sofitel Riyadh Hotel and Convention Centre. Among them are Prof. Jin-Soo Kim of KAIST, whose work on mitochondrial DNA editing reaches beyond CRISPR; Dr. Matthew H. Porteus of Stanford University, engineering genetic circuits into cell-based medicines; Dr. Alex Shalek of MIT; Prof. Vijay Kuchroo of Harvard Medical School; Prof. Keith T. Flaherty of the Massachusetts General Hospital Cancer Center and President of the American Association for Cancer Research; Prof. George F. Gao of the Chinese Academy of Sciences; President Mitsuo Ochi of Hiroshima University; and Dr. Zdenko Herceg of the International Agency for Research on Cancer. They are joined by the people who move science into the world. Dr. Steve Yang, Co-CEO of WuXi AppTec, and Mr. Alec Reynolds of Flagship Pioneering open the program on global partnership. Mr. Kasim Kutay, Chief Executive Officer of Novo Holdings, speaks on where capital should go next. Dr. Hyun-Young Park, Deputy Minister of the Korea National Institute of Health, delivers the closing keynote. Alongside them stand the Saudi institutions building a biotechnology sector in real time: KAIMRC, Lifera, HUMAIN, SPIMACO, KAUST, the Saudi Food and Drug Authority, and Astronaut Rayyanah Barnawi on what the human immune system does in space. The program runs across six tracks: artificial intelligence in biotechnology, multi-omics, biotech investment, immunology, bioengineering and synthetic biology, and biotech workforce development. Its defining feature is that discovery and delivery share the same stage. Genome editing and population genomics sit beside regulation, domestic manufacturing, and procurement, and in several sessions the scientists and the regulators are on the same panel. That is the premise of the Kingdom's National Biotechnology Strategy, which targets $34.6 billion in non-oil GDP from biotechnology by 2040: a discovery is worth only as much as the system available to carry it to a patient. "Biotechnology is where the health of every nation will be decided over the next twenty years. Saudi Arabia has chosen not to watch that happen from a distance. We are building the laboratories, the manufacturing, the regulatory ecosystems, and above all, the bio-workforce talent. And we are building it in partnership with the world, under one roof. That is what this Summit is for. Its themes highlight where medicine and biotechnology converge to shape the future of biosciences. Discoveries and breakthroughs are transforming how we care for patients. The diversity of emerging technologies and therapies is creating significant opportunities to explore, advance, invest, and translate scientific progress into better health outcomes. Please join us in Riyadh this September." H.E. Prof. Bandar bin Abdulmohsen Al-Knawy, Chief Executive Officer of Health Affairs, Ministry of National Guard, and President, King Saud bin Abdulaziz University for Health Sciences The Summit is organized and supervised by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by King Abdullah International Medical Research Center (KAIMRC) and King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), with the Ministry of Investment and Invest Saudi serving as strategic partners. The fourth edition is expected to welcome more than 15,000 visitors, over 200 biotechnology and healthcare brands, and delegations from more than 70 countries, under the theme Building the Foundations of Biotechnology Excellence. The full scientific program is attached and available at rgmbs.org, where registration is open for delegates, exhibitors, and industry partners. Follow the Summit at #RGMBS2026. For further information regarding summit programing visit: https://rgmbs.org/program#conference-agenda About the Riyadh Global Medical Biotechnology Summit The Riyadh Global Medical Biotechnology Summit is the Kingdom of Saudi Arabia's flagship platform for medical biotechnology, convening the global scientific, investment, and policy communities in Riyadh. Organized and supervised by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by KAIMRC and KSAU-HS, the Summit advances the goals of the National Biotechnology Strategy and supports the Kingdom's emergence as a global destination for health innovation. The fourth edition takes place from 14 to 16 September 2026 in Riyadh. For Media Inquiry Email: [email protected] Telephone: +966 559 810 777
- ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages The Simply Good Foods Company Investors to Secure Counsel Before Important Deadline in Securities Class Action – SMPLWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of The Simply Good Foods Company (NASDAQ: SMPL) between October 24, 2024 and April 8, 2026, inclusive (the “Class Period”), of the important October 13, 2026 lead plaintiff deadline.
- Sinless Vodka Cocktails Finds Gen Z May Be the Thirstiest Generation YetNew "Modern Dating Sindex" finds Gen Z experiences more double texting, love bombing, breadcrumbing and ghosting than Millennials